The pharmaceutical organization was looking for a reliable digital health partner to co-develop and co commercialize a regulated, highly scalable, standalone SaMD to complement its rare disease portfolio.
A global pharmaceutical company headquartered in Europe with a presence in 50+ countries, specializing in cardio-pulmonary rare diseases and neurological disorders across R&D, Digital Health and Technology, and manufacturing.
The pharmaceutical organization was looking for a mature regulated digital health partner that can fast track a regulated SaMD development for its rare disease management portfolio. Our partner was looking for a partner with a robust platform, user centric design, regulation and clinical expertise to de risk their SaMD development journey.
Wellthy Therapeutics was selected as the partner of choice for the co-development of a regulated digital health solution in the rare disease portfolio. With Wellthy’s proprietary wellthy CARE™ DTx platform, and a proven expertise of working with global pharmaceutical organizations, we developed a regulated SaMD solution in just 7 months
